Tertuliano Alves Pereira Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tertuliano Alves Pereira Neto has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Sette
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA
2 shared publications Adam Abawi
Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA
1 shared publicationAlba Grifoni
Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA
1 shared publication- Alba Grifoni
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA
1 shared publication Alessandro Antônio Costa Pereira
Departamento de Patologia e Parasitologia, Universidade Federal de Alfenas, Alfenas, MG, Brazil
1 shared publication- Alison Tarke
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA
1 shared publication
Latest Publications
- Open Access
Refinement of the Pathogenic T Cell Receptor Motif Suggests Type 17 CD8+ T Cells Initiate HLA-B*27-associated Autoimmunity
Human leukocyte antigen B*27 (HLA-B*27) is a major risk factor for autoimmune diseases such as axial spondyloarthritis (axSpA), acute anterior uveitis (AAU), and psoriatic arthritis (PsA). HLA-B*27 presents bacterial and self-antigens to disease-associated CD8+ T cells, however, how this leads to a pathogenic IL-17-mediated disease remains unclear. We performed mutational experiments in an established disease-associated TCR and demonstrated that the pathogenic motif encompasses a wider range of TCR sequences than previously appreciated. We next leveraged computational pairing of alpha/beta TCR sequencing (TCR-seq) to demonstrate that the broadened pathogenic motif distinguishes axSpA and AAU patients from healthy controls. Paired single-cell RNA sequencing and single-cell TCR sequencing datasets demonstrated that the pathogenic cells have a distinct transcriptional signature. We find a coupling of pathogenic TCRs to this transcriptional signature in public datasets from axSpA and PsA joint fluid and AAU ocular fluid. Finally, we detect the pathogenic CD8+ T cells in the gut and demonstrate that they express a Type 17 program. Our findings suggest that HLA-B*27+ axSpA, AAU, and PsA are initiated by HLA-B*27-restricted pathogenic CD8+ T cells that undergo Type 17 differentiation in response to intestinal antigens. One Sentence Summary: Multiple HLA-B*27-associated autoimmune diseases share the same pathogenic CD8+ T cells with Type 17 gene expression and cytokine production.
Open AccessRefinement of the Pathogenic T Cell Receptor Motif Suggests Type 17 CD8+ T Cells Initiate HLA-B*27-associated Autoimmunity
Human leukocyte antigen B*27 (HLA-B*27) is a major risk factor for autoimmune diseases such as axial spondyloarthritis (axSpA), acute anterior uveitis (AAU), and psoriatic arthritis (PsA). HLA-B*27 presents bacterial and self-antigens to disease-associated CD8+ T cells, however, how this leads to a pathogenic IL-17-mediated disease remains unclear. We performed mutational experiments in an established disease-associated TCR and demonstrated that the pathogenic motif encompasses a wider range of TCR sequences than previously appreciated. We next leveraged computational pairing of alpha/beta TCR sequencing (TCR-seq) to demonstrate that the broadened pathogenic motif distinguishes axSpA and AAU patients from healthy controls. Paired single-cell RNA sequencing and single-cell TCR sequencing datasets demonstrated that the pathogenic cells have a distinct transcriptional signature. We find a coupling of pathogenic TCRs to this transcriptional signature in public datasets from axSpA and PsA joint fluid and AAU ocular fluid. Finally, we detect the pathogenic CD8+ T cells in the gut and demonstrate that they express a Type 17 program. Our findings suggest that HLA-B*27+ axSpA, AAU, and PsA are initiated by HLA-B*27-restricted pathogenic CD8+ T cells that undergo Type 17 differentiation in response to intestinal antigens. One Sentence Summary: Multiple HLA-B*27-associated autoimmune diseases share the same pathogenic CD8+ T cells with Type 17 gene expression and cytokine production.
- Open Access
- 19 February 2026
- Published by Elsevier in Clinical Immunology Communications
- Vol. 9, 71-79
Discordant outcomes of SARS-CoV-2 exposure in household contacts
- 19 February 2026
- Published by Elsevier in Clinical Immunology Communications
- Vol. 9, 71-79
Open AccessDiscordant outcomes of SARS-CoV-2 exposure in household contacts
- Open Access
- 14 November 2023
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (12) , 1534
Correction: Correlative CD4 and CD8 T-cell immunodominance in humans and mice: implications for preclinical testing
- 14 November 2023
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (12) , 1534
Open AccessCorrection: Correlative CD4 and CD8 T-cell immunodominance in humans and mice: implications for preclinical testing
- Open Access
Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model
The Zika virus (ZIKV) was first isolated from a rhesus macaque in the Zika forest of Uganda in 1947. Isolated cases were reported until 2007, when the first major outbreaks of Zika infection were reported from the Island of Yap in Micronesia and from French Polynesia in 2013. In 2015, ZIKV started to circulate in Latin America, and in 2016, ZIKV was considered by WHO to be a Public Health Emergency of International Concern due to cases of Congenital Zika Syndrome (CZS), a ZIKV-associated complication never observed before. After a peak of cases in 2016, the infection incidence dropped dramatically but still causes concern because of the associated microcephaly cases, especially in regions where the dengue virus (DENV) is endemic and co-circulates with ZIKV. A vaccine could be an important tool to mitigate CZS in endemic countries. However, the immunological relationship between ZIKV and other flaviviruses, especially DENV, and the low numbers of ZIKV infections are potential challenges for developing and testing a vaccine against ZIKV. Here, we discuss ZIKV vaccine development with the perspective of the immunological concerns implicated by DENV-ZIKV cross-reactivity and the use of a controlled human infection model (CHIM) as a tool to accelerate vaccine development.
Open AccessPeculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model
The Zika virus (ZIKV) was first isolated from a rhesus macaque in the Zika forest of Uganda in 1947. Isolated cases were reported until 2007, when the first major outbreaks of Zika infection were reported from the Island of Yap in Micronesia and from French Polynesia in 2013. In 2015, ZIKV started to circulate in Latin America, and in 2016, ZIKV was considered by WHO to be a Public Health Emergency of International Concern due to cases of Congenital Zika Syndrome (CZS), a ZIKV-associated complication never observed before. After a peak of cases in 2016, the infection incidence dropped dramatically but still causes concern because of the associated microcephaly cases, especially in regions where the dengue virus (DENV) is endemic and co-circulates with ZIKV. A vaccine could be an important tool to mitigate CZS in endemic countries. However, the immunological relationship between ZIKV and other flaviviruses, especially DENV, and the low numbers of ZIKV infections are potential challenges for developing and testing a vaccine against ZIKV. Here, we discuss ZIKV vaccine development with the perspective of the immunological concerns implicated by DENV-ZIKV cross-reactivity and the use of a controlled human infection model (CHIM) as a tool to accelerate vaccine development.
DC‐SIGN and VDR polymorphisms are associated with chronic form of paracoccidioidomycosis with oral manifestations
Summary: Paracoccidioidomycosis (PCM) is a granulomatous disease caused by fungi of the species complex of the Paracoccidioides genus. One of the main clinical manifestations of PCM is the presence of oral lesions with the presence of epithelioid granulomas. In this work, we aimed to evaluate the frequency of SNPs in the TNF‐α, JAK1, VDR, DC‐SIGN and FcγRIIa genes in patients with chronic PCM and verify possible association of these SNPs with the organisation pattern of the granulomas in the oral lesions. A total of 66 samples of DNA were obtained from oral lesions biopsies and 106 DNA samples were obtained from healthy individuals. The individuals were genotyped for SNPs in DC‐SIGN (rs4804803), FcγRIIa (rs1801274), JAK1 (rs11208534), TNF‐α (rs1800629) and VDR (rs7975232) by real‐time PCR and allele discrimination method. Granulomas were classified as loose or dense according to the histological pattern. In the VDR (rs7975232), the CC genotype (P < 0.001, OR = 5.94, 95% CI = 2.07‐17.05), and the C allele (P = 0.027, OR = 2.71, 95% CI = 1.07‐6.86), as well as the GG genotype in DC‐SIGN (rs4804803) (P = 0.032, OR: 3.76, 95%, I = 1.06‐13.38) are associated with an increased risk of oral PCM. Our data indicate that VDR and DC‐SIGN genetics variations are related to the susceptibility of oral PCM in the group of patients analysed.
DC‐SIGN and VDR polymorphisms are associated with chronic form of paracoccidioidomycosis with oral manifestations
Summary: Paracoccidioidomycosis (PCM) is a granulomatous disease caused by fungi of the species complex of the Paracoccidioides genus. One of the main clinical manifestations of PCM is the presence of oral lesions with the presence of epithelioid granulomas. In this work, we aimed to evaluate the frequency of SNPs in the TNF‐α, JAK1, VDR, DC‐SIGN and FcγRIIa genes in patients with chronic PCM and verify possible association of these SNPs with the organisation pattern of the granulomas in the oral lesions. A total of 66 samples of DNA were obtained from oral lesions biopsies and 106 DNA samples were obtained from healthy individuals. The individuals were genotyped for SNPs in DC‐SIGN (rs4804803), FcγRIIa (rs1801274), JAK1 (rs11208534), TNF‐α (rs1800629) and VDR (rs7975232) by real‐time PCR and allele discrimination method. Granulomas were classified as loose or dense according to the histological pattern. In the VDR (rs7975232), the CC genotype (P < 0.001, OR = 5.94, 95% CI = 2.07‐17.05), and the C allele (P = 0.027, OR = 2.71, 95% CI = 1.07‐6.86), as well as the GG genotype in DC‐SIGN (rs4804803) (P = 0.032, OR: 3.76, 95%, I = 1.06‐13.38) are associated with an increased risk of oral PCM. Our data indicate that VDR and DC‐SIGN genetics variations are related to the susceptibility of oral PCM in the group of patients analysed.